James is a co-founder and partner at ExSight Ventures where he has helped lead the firm’s investments in twelve transformative ophthalmic companies. He serves on the ExSight investment committee and helms the firm’s operations. His duties include sourcing and evaluating early-stage companies, assisting current and prospective portfolio companies, and is responsible for the firm’s operational functions. He serves on the board of Re-Vana Therapeutics, Ltd, a Northern Ireland ocular pharmaceuticals and drug delivery company, Usher III Initiative, a nonprofit dedicated to finding treatments for individuals with Usher III, and Nectar Services, an unaffiliated New York UCaaS company. James is a board observer at 2C Tech, a California company pioneering nanoparticle technology to treat blinding ophthalmic disease. Prior to co-founding ExSight Ventures, James held various positions at a New York City asset management company, eventually serving as General Counsel and Head of Strategic Initiatives. James is admitted to practice in the State of New York. He is a member of the Association of the Bar of the City of New York where he is a member (and former chair) of the Emerging Companies Committee. James received his B.A., cum laude, from Canisius College and his J.D. from Brooklyn Law School.